Biomarkers for the prediction and monitoring of the antipsychotic/antidepressant-induced hepatotoxicity: study protocol
Open Access
- 11 December 2024
- journal article
- research article
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 25 (16-18) , 667-678
Abstract
This study is designed to address the connection between antidepressant and antipsychotic-induced hepatotoxicity with pharmacogenetic and epigenetic indicators, using a novel combined approach of CYP450 polymorphism determination and early liver injury detection via microRNA testing. The multi-centric retrospective case-control study in Slovakia involves 151 cases with signs of hepatotoxicity and 604 controls without. Participants will be tested for selected CYP450, UGT1A1 polymorphisms, and microRNAs. Anticipated findings will test if patients with specific CYP450 and UGT1A1 polymorphisms are at higher risk for drug-induced hepatotoxicity and if plasma microRNAs hsa-miR-122-5p and hsa-miR-192-5p, alone or combined, can differentiate patients with abnormal liver function. The findings could contribute to personalized treatment approach by combining genetic and epigenetic biomarkers.Keywords
Funding Information
- Grant Univerzity Komenského
This publication has 54 references indexed in Scilit:
- Approaches and hurdles of implementing pharmacogenetic testing in the psychiatric clinicPsychiatry and Clinical Neurosciences Reports, 2022
- Systems analysis of miRNA biomarkers to inform drug safetyArchives of Toxicology, 2021
- An Evidence‐Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized MedicineClinical Pharmacology & Therapeutics, 2021
- Antidepressants- and antipsychotics-induced hepatotoxicityArchives of Toxicology, 2021
- The implementation of pharmacogenomics into UK general practice: a qualitative study exploring barriers, challenges and opportunitiesJournal of Community Genetics, 2020
- Epidemiology, Predisposing Factors, and Outcomes of Drug-Induced Liver InjuryClinics in Liver Disease, 2020
- MicroRNAs as biomarkers for liver injury: Current knowledge, challenges and future prospectsFood and Chemical Toxicology, 2017
- The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature DatabaseClinical Pharmacology & Therapeutics, 2017
- DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humansDrug Discovery Today, 2016
- Identification and characterization of potent CYP2D6 inhibitors in lotus leavesJournal of Ethnopharmacology, 2014